Hana Brellah Pharm D

 Credited with leading the development of the Ophthalmology franchise from the bottom up including, but not limited to, business development, mergers, and acquisitions, resulting in a 60% growth rate in 2 years.  Drove Mundipharma to rank among the Top 3 Best Vision Care pharmaceutical companies in 2017, and as one of the Top 10 Fastest Growing pharmaceutical companies in the META region.

 Contributed to Northwest Africa and Malta top ranking for small affiliates through double-digit growth.  Strongly contributed to a 90% awareness rate by physicians of INF free HCV treatment.  Facilitated the implementation of the HCV capacity disease management software for health care professionals in Algeria, Morocco, and Tunisia.

 Algeria Ophthalmology achieved the #1 Ranking in the EEMEA for the Ophthalmology Franchise by achieving 65% growth in internal sales performance, and the highest share in the market (IMS 2013).  Won multiple awards for strategic planning and leading team achievement.

 Accomplished 3X increase in monthly modern insulin consumption, which drove Novo Nordisk to achieve market share leader status in fact-acting insulin and Metformin.  Recognized by 90% of doctors who positively perceived NovoRapid as the gold standard in fast-acting insulin.  Coached and mentored the sales team to implement programs with the highest quality.

Established and managed multiple therapeutic areas by establishing a marketing department with consistent collaboration with the head office in Switzerland.  Developed 3 franchises from the bottom-up, including gastrointestinal, neuropsychiatry, and cardiology. Achieved consistent highest market share of a variety of generic brands.